Dr. Helen Heslop elected to the National Academy of Medicine
Election to the National Academy of Medicine recognizes outstanding professional achievement and commitment to service.
Read MoreElection to the National Academy of Medicine recognizes outstanding professional achievement and commitment to service.
Read MoreAn 18-year survivor of neuroblastoma is believed to represent the longest reported remission to date in a patient treated with chimeric antigen receptor (CAR) T cell therapy.
Read MoreResearchers relate their journey to finding a promising method to address CAR T cell challenges in treating solid tumors.
Read MoreThe CPRIT awards support developmental research focusing on promising new insights into cancer treatment and innovative core facilities.
Read MoreThis study shows that this therapy can effectively get to the tumor, and the addition of C7R safely augments antitumor activity.
Read MoreNon-Hodgkin’s lymphoma patient Matt Rea flew to Houston to receive CD19 CAR-T cells from his identical twin brother Will Rea.
Read MoreThe HEROS 2.0 trial showed that this therapeutic approach is safe and is associated with clinical benefit.
Read MoreA first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of anti-tumor efficacy and safety.
Read MoreThe findings support further assessing this approach to treat aggressive blood cancers and ultimately improve outcomes in patients.
Read MoreBaylor College of Medicine researchers extend the life and effectiveness of off-the-shelf, cancer-fighting immune T cells.
Read More